Characterization and clinical prioritization of neurotoxicity-related safety signals associated with lithium and haloperidol co-administration: A pharmacovigilance study based on FAERS
Journal of Affective Disorders · 2026-11 · 413 · 122241
DOI: 10.1016/j.jad.2026.122241 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Affective Disorders, 2026-11. Verfasst von Chaoxiong Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Jiangxi Mental Hospital & Affiliated Mental Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330029, Jiang…. Hauptthemen laut MEDLINE: Haloperidol, Pharmacovigilance, Neurotoxicity Syndromes, Lithium Carbonate. Die Arbeit nennt 47 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: The concurrent use of lithium carbonate and haloperidol is common in psychiatric practice, yet it remains unclear which neurotoxicity-related adverse events are specific to the combination rather than to either agent alone. This study aimed to identify and prioritize the neurotoxicity-related manifestations potentially associated with this drug combination. METHODS: Neurological and psychiatric adverse event reports were extracted from FAERS covering Q1 2004 through Q4 2025 and stratified into lithium reports without haloperidol, haloperidol reports without lithium, and combination co-administration reports. Drug-event-pair-based reporting odds ratios were used for signal estimation, while report-level dual-comparator screening was used to retain co-administration-associated signals. Retained signals were ranked using a semi-quantitative clinical prioritization system. Sensitivity analysis under a stricter exposure definition assessed robustness. RESULTS: A total of 9745 target reports were included (combination co-administration: 429; lithium without haloperidol: 3688; haloperidol without lithium: 5628). Twenty-eight reporting signals were more frequently reported with co-administration than with reports involving either target drug without the other in the main analysis, with 14 retained after sensitivity analysis. Neuroleptic malignant syndrome, neurotoxicity, encephalopathy, and delirium remained moderate-priority signals in both analyses. CONCLUSION: Neurotoxicity, neuroleptic malignant syndrome, encephalopathy, and delirium warrant prioritized clinical attention during lithium carbonate and haloperidol co-administration. These hypothesis-generating findings support targeted neurological and neuropsychiatric monitoring for patients receiving this combination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Jiangxi Mental Hospital & Affiliated Mental Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330029, Jiangxi, China; Nanchang City Key Laboratory of Biological Psychiatry, Jian…
Zitieren
APA
Zhou, C., Zheng, L., Wu, X., Xiong, J., & Zhang, S. (2026). Characterization and clinical prioritization of neurotoxicity-related safety signals associated with lithium and haloperidol co-administration: A pharmacovigilance study based on FAERS. Journal of Affective Disorders, 413, 122241. https://doi.org/10.1016/j.jad.2026.122241
Vancouver
Zhou C, Zheng L, Wu X, Xiong J, Zhang S. Characterization and clinical prioritization of neurotoxicity-related safety signals associated with lithium and haloperidol co-administration: A pharmacovigilance study based on FAERS. Journal of Affective Disorders. 2026;413:122241. doi:10.1016/j.jad.2026.122241
BibTeX
@article{Zhou2026,
author = {Zhou, Chaoxiong and Zheng, Liyun and Wu, Xiaopeng and Xiong, Jianwen and Zhang, Shuang},
title = {Characterization and clinical prioritization of neurotoxicity-related safety signals associated with lithium and haloperidol co-administration: A pharmacovigilance study based on FAERS},
journal = {Journal of Affective Disorders},
year = {2026},
volume = {413},
pages = {122241},
doi = {10.1016/j.jad.2026.122241}
}
EUVIMED